12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Deals

MolMed, Fondazione deal

MolMed and Fondazione partnered to develop treatments for genetic diseases associated with a single genetic defect. The diseases include metachromatic leukodystrophy (MLD); Wiskott-Aldrich syndrome (WAS); beta-thalassemia; mucopolysaccharidosis type I (MPS-I); globoid...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >